IMDX - Insight Molecular Diagnostics Inc.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
As of May 15, 2026: spot at $6.37, ATM IV 134.5%, net GEX -$930.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $136.9M
- Beta
- 1.63
- 52-Week Range
- 2.33-8.51
- CEO
- Joshua Riggs
- Employees
- 46
- IPO Date
- Dec 30, 2015
- Exchange
- NASDAQ
What IMDX Looks Like to Options Traders Today
negative net gamma exposure (-$930) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (1.321) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The IMDX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked IMDX overview questions
- What is IMDX?
- IMDX is the ticker symbol for Insight Molecular Diagnostics Inc., a listed security. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. Listed on NASDAQ. IMDX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the IMDX options snapshot look like today?
- As of May 15, 2026, the IMDX options snapshot shows spot at $6.37, ATM IV 134.5%, net GEX -$930, expected move 38.56%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are IMDX's key statistics?
- Insight Molecular Diagnostics Inc. (IMDX) carries a market capitalization of $136.9M, beta of 1.63 relative to the broader market, 52-week range of 2.33-8.51. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does IMDX belong to?
- Insight Molecular Diagnostics Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare IMDX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the IMDX data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).